Vertex Pharmaceuticals Inc. hit a major milestone on Thursday when the U.S. Food and Drug Administration approved its ...
Vertex Pharma has secured FDA approval for its non-opioid pain drug suzetrigine, becoming the first new class of pain ...
Vertex Pharmaceuticals (Nasdaq: VRTX) announced today a reimbursement agreement with NHS England for eligible sickle cell disease (SCD) patients to access the CRISPR/Cas9 gene-edited therapy, CASGEVY® ...
Today, the U.S. Food and Drug Administration approved Journavx (suzetrigine) 50 milligram oral tablets, a first-in-class ...
2don MSN
Google just dropped 4 new Gemini 2.0-series models, with some designed for coding performance and complex prompts and the ...
Financial writer recommends Crispr Therapeutics AG as a strong buy due to cash position, drug pipeline, and promising ...
Because the drug doesn’t target the brain, it has less potential for addiction. Learn why this could help the opioid crisis.
The National Institute for Health and Care Excellence (NICE) has approved Vertex Pharmaceuticals’ Casgevy (exagamglogene ...
If the drug is approved by the US Food and Drug Administration for the treatment of acute pain in January as expected, the ...
Mistral, the company sometimes considered Europe’s great hope for AI, is releasing several updates to its AI assistant, Le ...
NEW YORK, NY / ACCESS Newswire / February 4, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex ...
This new nonaddictive alternative is the first of its kind that interrupts the pain signal before it reaches the brain.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback